ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027

ArriVent BioPharma, Inc.

Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).
Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.
Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.
ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ArriVent BioPharma, Inc. reported the year ended December 31, 2025 results: net income Net loss was $166.3 million.

Period: the year ended December 31, 2025
Net income: Net loss was $166.3 million
Result: reported results

Exact text from the filing

ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-024112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.